Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Feb 24;7(3):e843. doi: 10.1097/HS9.0000000000000843

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association.

This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

PMC Copyright notice

Figure 1. — Proportion improved/stable/worsened patients for (A) MDASI-MM total symptom score, (B) MDASI-MM symptom interference, and (C) EQ-5D-3L VAS at each on-treatment cycle. (A) Responder definition was −0.4 for improvement and +0.4 for worsening HRQoL; (B) Responder definition was −0.7 for improvement and +0.7 for worsening HRQoL; (C) Responder definition was +7 for improvement and −7 for worsening HRQoL. For all graphs (A–C), response calculated relative to baseline; number of patients presented within bars. EPd = elotuzumab + pomalidomide + dexamethasone; EQ-5D-3L = 3-level EuroQol 5 dimension; HRQoL = health-related quality of life; MDASI-MM = MD Anderson Symptom Inventory for Multiple Myeloma; Pd = pomalidomide + dexamethasone; VAS = visual analog scale.